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Abstract  
AIM: The current study was designed to investigate the effectiveness of locally applied Strontium ranelate to 
induce bone formation. 
MATERIALS AND METHODS: Forty-eight female rats were divided into six groups (eight rats in each group): 
The three test groups included Strontium (SR) 2.5 mg, 5 mg and 10 mg that was dissolved in methylcellulose gel. 
The control groups included methylcellulose, simvastatin 5 mg and a negative control where the defect was left to 
heal without any intervention. At 44 days the groups were sacrificed, and the bone defects were assessed 
histomorphometically to assess bone formation. The data was statistically analysed. 
RESULTS: There was a statistically significant difference in the amount of new bone formation between all 
groups, where the 2.5 mg SR group showed the highest median bone percentage, is 41.95 %, followed by the 5, 
and 10 mg SR demonstrating a median bone are a percentage of 39.89%, and 30.19% respectively. Simvastatin 
showed a median bone percentage of 36.07 %, while the methylcellulose and the negative control groups 
demonstrated the lowest median area percentage of 23.12 and 20.70 % respectively. 
CONCLUSIONS: The study showed that the local application of an SR could up-regulate the bone formation and 
may prove to be a cost-effective method of bone regeneration. 
 
 
 
 
Introduction 
 
Epidemiological studies have shown that 50% 
of the adult population between the ages of 45 and 65 
years exhibited bone loss around teeth that are 
caused by periodontal disease. Various materials 
have been proposed to treat the bone defects which 
are a hallmark of the periodontal disease. The 
stimulation of local bone formation could positively 
affect the healing of isolated bony defects [1, 2]. 
Growth factors have exhibited the ability to induce 
bone formation [3]. On the other hand host tissues as 
well as a possible antibody response decreased the 
appeal for growth factor utilization. 
The local application of systemic bone 
modulating drug that is commonly used to treat bone 
disease could offer a plausible alternative to growth 
factors. The advantage of local drug delivery is 
releasing the drug directly into the site of infection for 
a sufficient period without systemic exposure 
preventing both bacterial resistance and drug-related 
systemic side effects [4]. 
Various drugs have been studied using local 
delivery to improve the periodontal health and to 
achieve periodontal regeneration. Pharmacological 
agents offer great promise in this direction. 
Simvastatin, a widely used cholesterol-lowering drug, 
was shown to stimulate bone both in vitro and in vivo 
when applied locally, and its effects on bone 
metabolism favour its use in the treatment of 
periodontal defects. Additional advantages of 
simvastatin are its antioxidant and anti-inflammatory 
properties which could further facilitate healing of 
periodontal intrabony defects [5, 6]. 
Strontium ranelate (SR), a drug licensed for 
the treatment of postmenopausal osteoporosis is 
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composed of an organic moiety (ranelic acid) and two 
atoms of stable strontium. In contrast to most currently 
used drugs currently that inhibit bone resorption rather 
than stimulating bone formation, SR has a novel mode 
of action, both increasing bone formation and 
reducing bone resorption, rebalancing bone turnover 
in favor of bone formation and increases bone 
strength It has a dual mode of action, both increasing 
bone formation and decreasing bone resorption [7-9]. 
The mechanism behind its dual mode of action was 
explained in several studies as by enhancing 
osteoblastic cell replication and activity and 
decreasing preosteoblast differentiation and 
osteoclastic activity [9, 10]. 
In an experiment that was conducted to 
examine the cytotoxicity of SR on human periodontal 
ligament (PDL) fibroblasts, SR was found to be non-
toxic at appropriate concentrations. In the experiment, 
PDL cells were treated with SR at 20, 10, 5 and 2.5 
mg/ml. The highest SR concentrations (20 and 10 mg) 
had significantly lower cell viability and cell numbers 
than those in 5 and 2.5 mg/ml. The author 
recommended the need for preclinical tests to further 
assess its safety and effectiveness before clinical use 
[11]. 
Methylcellulose has been used as a drug 
carrier for releasing in several pharmaceutical 
preparations because it is a harmless, nontoxic 
material that does not sensitise the tissues [12]. 
The critical-size rat calvarial defect is a 
convenient model for evaluating bone regenerative 
effects of bio-materials. It is accessible, simple and is 
unable to regenerate spontaneously because of the 
distance that the progenitor cells and blood vessels 
must travel from the healing margin to bridge the 
defect is great [13, 14]. In rat calvaria, the defect is 8 
mm and is well suited for placement of particulate 
materials [15]. 
The purpose of this study was to evaluate 
qualitatively and quantitatively the ability of strontium 
ranelate to induce bone regeneration in rat critical-
sized bone defects  
 
 
Methods 
 
Experimental design 
The animal protocol was approved by the 
Ethical Committee of the National Research Centre, 
Cairo, Egypt. Forty-eight adult Sprague-Dawley rats 
(275 to 300 g) were randomly divided into six groups 
of eight animals each: The three test groups included 
Strontium 2.5 (SR), 5 mg and 10 mg that was 
dissolved in methylcellulose gel. The control groups 
included methylcellulose, simvastatin 1.2 mg and a 
negative control where the defect was left to heal 
without any intervention. In all group except the 
negative control group the gel was applied to the 
defect and at 44 days the groups were sacrificed and 
the bone defects were assessed histomorphometically 
to assess bone formation: Formulation of Strontium 
Ranelate (SR) gel A 4.0% (w/v) methylcellulose 
(4,000 cps) gel, (Sigma chemicals Co., St . Louis, 
MO), which served as the vehicle for SR was 
previously prepared, by adding the required amount of 
polymer to hot distilled water and cooling to gel at 
room temperature. Then 2.5, 5 and 10 mg of SR (EVA 
pharmaceuticals, Cairo, Egypt )was dissolved in 1 ml 
of methylcellulose [16]. 
 
Surgical Protocol 
Animals were sedated using an intramuscular 
injection of two parts ketamine (100 mg/ml) Ketamar 
100 (mg/ml) Amoun and one part xylazine (20 mg/ml) 
Xylazine Albrecht, Germany; Ceva, Germany; 
Serumber, Germany at a dosage of 0.2 ml/100 g, 
additional sedation was given if needed. Routine 
infiltration anaesthesia with 2% lidocaine and 
1:100,000 epinephrine (Octacaine) was used at the 
surgical site. 
An incision was made in the sagittal plane 
across the cranium, and a full-thickness flap was 
reflected, exposing the calvarial bone. A standardised, 
circular, transosseous defect, 8 mm in diameter, was 
created on the cranium with the use of a saline-cooled 
trephine drill (Biomet 3i, Palm Beach Gardens, USA). 
An 8 mm dental trephine was used to create a 
standardised, circular, transosseous defect, 8 mm in 
diameter, of the rat calvaria. The trephined calvarial 
bone was then carefully removed to avoid perforation 
of the dura mater.  
To achieve standardisation 1 ml of the 
formula (either methylcellulose alone, with simvastatin 
or with strontium) was injected within the created 
defect. 
In the first three groups, a 2.5, 5 and 10 
mg/ml dose of SR added to an inert methylcellulose 
gel was inserted into the defect. The two positive 
control groups included a group were 5 mg of 
simvastatin dissolved in methylcellulose and a group 
of one ml of methylcellulose gel that was added to 
critical defect size. No material was added to the last 
group acting as a negative control, where the defect 
was left to heal without any intervention. The 
periosteum and skin were then closed and sutured 
with 4-0 Egysorb, (Taisier - med, Egypt). The animals 
were sacrificed after 44 days using CO2 asphyxiation. 
 
Sample Preparation 
The calvarium was removed, and the 
specimens were fixed in 10% formalin for 48 hours. 
Specimens were then transferred to the decalcifying 
solution (RDO Apex Engineering Products 
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Corporation, IL - USA). After 72 hours, specimens 
were processed through ascending grades of alcohol, 
cleared in xylene and embedded in paraffin. Formalin-
fixed, decalcified, paraffin-embedded tissue blocks 
were obtained. Paraffin sections of 5-micron thickness 
were prepared from each of the paraffin blocks with a 
longitudinal cut to show the defect with the 
surrounding bone healing. For routine 
histopathological examination, slides were stained 
with Hematoxylin & Eosin (H&E) stain. Assessment of 
new bone formation and morphometric analysis were 
performed on Masson trichrome-stained sections, 
where the mineralised bone was stained red, osteoid 
dark bluish green and collagen fibres greenish blue. 
 
Histomorphometric Analysis 
A quantitative study was obtained with the aid 
of Leica Qwin 500 LTD (Leica Microsystem 
Corporation, Cambridge, England) using the software 
Quin 500 (England). The slides were examined using 
power magnification X 100 for measurement of area 
percent of newly formed bone detected by Masson 
trichrome stain. The red stained areas were outlined 
and then measured in micrometre square in 
successive fields of the section and the total new 
bone formation in the specimen was then calculated 
automatically by the morphometry software. 
 
Statistical Analysis 
Numerical data were explored for normality by 
checking the data distribution and using Kolmogorov-
Smirnov and Shapiro-Wilk tests. Data showed non-
parametric distribution. Data were represented by 
median and range values. Kruskal - Wallis test was 
used to compare the different groups. Mann-Whitney 
U test with Bonferroni’s adjustment was used for 
pairwise comparisons between the groups. The 
significance level was set at P ≤ 0.05. Statistical 
analysis was performed with IBM® SPSS® Statistics 
Version 23 for Windows. 
  
 
Results 
 
Histopathological Results 
Histopathological examination showed areas 
filled with red blood cells, inflammatory cells and 
fibroblastic proliferation with neovascularisation and 
granulation tissue formation as well as mild 
osteoblastic proliferation with osteoid tissue was 
noticed together with few foci of disorganised woven 
bone formation especially at the periphery of the 
defect. The centre showed fewer areas of osteoid & 
bone formation. 
Strontium Treated Group 
The 2.5 and 5 mg groups showed more 
attempts at bone formation with less inflammatory 
reaction as compared to the control group. Moderate 
fibroblastic proliferation was seen with marked 
osteoblastic cells proliferation. More foci of 
disorganised, woven bone were observed with the 
more collagenous extracellular matrix. The active 
bone formation was suggested as newly formed 
osteoid was observed, in the form of spicules rimmed 
by numerous osteoblasts as well as osteoid tissue 
having viable osteocytes within widened lacunae. 
Changes were seen extending from the margins down 
to the centre of the defect (Fig. 1).  
 
Figure 1: Photomicrograph of the methylcellulose  group showing 
areas of osteoid formation and collagen without evidence of 
maturation (Masson trichrome, original magnification X 100) 
 
The 10 mg group showed no osteoblastic 
proliferation at all. Large areas were filled with 
fibroblasts, and collagen fibres with heavy 
inflammatory cell infiltrate (Fig. 2). 
 
 
Figure 2: Photomicrograph of the 5mg strontium  group showing 
areas of osteoid and woven bone formation with large marrow 
cavities (Masson trichrome, original magnification X 100) 
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Simvastatin Treated Group 
The simvastatin group showed large, 
alternating areas of lamellar and woven bone 
formation with marked osteoblastic rimming and 
proliferation. No inflammatory cell infiltrate was 
detected. The new bone filled the margins of the 
defect till the centre (Fig. 3). 
 
Figure 3: Photomicrograph of the 10mg strontium group showing 
large areas of collagen fibres with no attempts at osteoid or bone 
formation (Masson trichrome, original magnification X 100) 
 
 
Negative control Group 
In the negative control groups, the limited 
bone repair was observed only at the margins of the 
defect, as recognised by the irregularly shaped bone 
trabeculae of newly formed mineralised bone and 
newly formed osteoid tissue. No bone formation or 
evidence of mineralization in the centre of the defect, 
where only a mature and well organized fibrous tissue 
was noticed. 
 
Figure 4: Photomicrograph of the simvastatin group showing large 
alternating areas of osteoid and woven bone formation (Masson 
trichrome, original magnification X 100) 
 
 
Statistical Results 
Descriptive statistics of area % values are 
presented in Table 1. There was a statistically 
significant difference between area % values of the 
different groups. Pair-wise comparisons between the 
groups revealed that there was no statistically 
significant difference between Strontium (2.5 mg), 
Strontium (5 mg) and Simvastatin with an as 
significant difference with Methylcellulose and 
Negative control. 
Table 1: Comparison between area % of the five groups 
Area % Median Minimum Maximum Rank p-value 
 
Strontium (2.5 mg) 41.95 22.15 44.05 a 
≤0.001* 
Strontium (5 mg) 39.89 19.56 57.25 a 
Strontium (10 mg) 30.19 16.09 46.96 ab 
Simvastatin 36.07 26.89 77.61 a 
Methylcellulose 23.12 11.01 30.48 b 
Negative control 20.70 10.50 23.70 b 
 *: Significant at P ≤ 0.05, Different letters in the same column are statistically significantly 
different 
For the negative control group, the maximum 
bone area percentage was 23.7%, while that of 
methylcellulose was 30.48%, both were statistically 
different than the strontium and simvastatin groups., 
where the strontium groups showed a maximum area 
percentage of 44.05, 57.25 and 46.96% for the 2.5, 5 
and 10 mg strontium respectively while that of 
simvastatin showed the higher area percentage with 
77.61%. 
  
 
Discussion 
 
The study aimed to evaluate the bone 
regenerative potential of locally applied SR in different 
concentrations. The rat calvarial critical-sized defect is 
a well-established animal model for regenerative bone 
studies. The bone defect of critical size is unable to 
regenerate. Thus it is considered to be a suitable for 
the evaluation of osteoinductivity of various materials. 
Only materials that can induce bone regeneration 
show signs of bone formation throughout the entire 
critical defect [16, 17]. 
SR was used as it showed promising results 
in osteoporosis therapy, where it is known to increase 
in vitro osteoblasts’ differentiation from progenitors, as 
well as osteoblastic activity and survival. Furthermore, 
SR regulates osteoblast - induced osteoclastogenesis, 
and prevents bone resorption by decreasing 
osteoclastic differentiation and activity, while 
increasing their apoptosis [18]. 
The incorporation of strontium into 
mesoporous bioactive glass scaffolds was shown to 
be a viable way to stimulate the biological response of 
periodontal ligament cells as well as stimulate bone 
formation in bone defects in an osteoporotic rat model 
[19, 20]. 
Previous studies showed that 44 days 
represent adequate timing to analyse newly formed 
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bone in rat calvarial defects [2]. The bone turnover 
rate of rats and the ability of fast healing make the 
evaluation of bone formation 6 to 8 weeks after 
implantation of a biomaterial appropriate. Thus no 
major differences are expected to be observed in 
bone formation even if prolonged healing time is 
allowed [16]. 
All defect sites exhibited bone formation, but 
there was a statistically significant difference in the 
amount of new bone formation between all groups, 
where the 2.5 SR group showed the highest median 
bone percentage, being 41.95 %, followed by the 5, 
and 10 mg SR demonstrating a median bone are 
percentage of 39.89%, and 30.19% respectively. 
Simvastatin showed a median bone percentage of 
36.07%, while the methylcellulose and the negative 
control groups demonstrated the lowest median area 
percentage of 23.12 and 20.70 % respectively. 
The histologic evaluation of the 2.5 and 5 mg 
groups showed more attempts at bone formation with 
less inflammatory reaction as compared to the control 
group. This could be attributed to the anti-
inflammatory effect of SR that has been proposed by 
due to the antagonising effect of SR to NF-κB 
activation. Furthermore, in unpublished data by the 
same group, they proposed that SR may act as TNF 
inhibitor which could explain its anti-inflammatory 
properties [21]. 
Bone defect healing occurs naturally after a 
phase of bleeding and inflammation and terminates 
with the formation of woven bone which is then 
remodelled by osteoclasts and replaced by lamellar 
bone by osteoblasts [3]. 
The osteoblasts presence was marked in the 
2.5 and 5 mg SR groups compared to the control 
group) which may be explained due to the fact that SR 
has the ability to stimulate PGE2 production and 
osteoblastic differentiation in marrow stromal cells, 
which is markedly affected by inhibition of COX-2 
activity or disruption of COX-2 gene expression [22]. 
Furthermore, [23] concluded that SR promotes the 
replication of osteoblasts which could explain the 
marked osteoblastic proliferation in the 2.5 and 5 mg 
SR groups. 
Woven osteoid bone and mineralised bone 
presence were marked in the SR group than by the 
control group. All these observations could be clearly 
to the dual effect of SR that promoted the bone 
formation on several levels and through various 
pathways. 
In the negative control groups, the limited 
bone repair was observed only at the margins of the 
defect, as recognised by the irregularly shaped bone 
trabeculae of newly formed mineralised bone and 
newly formed osteoid tissue. The findings of no bone 
formation or evidence of mineralization in the center of 
the defect, where only a mature and well organized 
fibrous tissue was noticed, is consistent with the 
calvarial nonunion defects study of [17] where both 
the central and peripheral regions of the 8 mm 
calvarial defects were characterized by dense fibrous 
tissue repair and inactive fibroblasts.  
Simvastatin was used in the present study as 
a positive control, to compare its effect on bone 
formation with that of SR, where former research 
demonstrated that local application of simvastatin in 
alveolar defects could promote bone regeneration 
[12]. In the present study large, areas of lamellar and 
woven bone formation with marked osteoblastic 
proliferation where demonstrated histologically, where 
the new bone filled the margins of the defect till the 
centre with no detected inflammatory cell infiltrates. 
The local application has been demonstrated anti-
inflammatory effects as well, anabolic effects on bone 
and a stimulatory effect on vasculogenesis which was 
attributed to the increase in the expression of BMP-2, 
and vascular endothelial growth factor [24] which may 
explain the results of the present study.Our findings 
are also in line with a former research that 
demonstrated the ability of local simvastatin 
application to enhance healing of the bone defects 
even in the diabetic rat models [25]. 
 In conclusion, the current study 
demonstrated that the local application of a single 
dose of SR (2.5 and 5 mg) could up-regulate the bone 
formation. The local application of SR may prove to be 
a cost-effective and safe method to stimulate bone 
formation. However more in vivo studies and different 
concentrations are recommended to define the 
optimal dose to equilibrate soft tissue inflammation 
and bone stimulation. 
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